Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS Mutations

NCT01320085 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01320085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01320085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS Mutations
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2011
Completion date
February 6, 2023
Enrollment
183 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

braf or nras mutant metastatic melanoma